ABCG2 p.Lys86Met

Predicted by SNAP2: A: D (95%), C: D (95%), D: D (95%), E: D (95%), F: D (95%), G: D (95%), H: D (95%), I: D (95%), L: D (95%), M: D (95%), N: D (95%), P: D (95%), Q: D (95%), R: D (95%), S: D (95%), T: D (95%), V: D (95%), W: D (95%), Y: D (95%),
Predicted by PROVEAN: A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, L: D, M: D, N: D, P: D, Q: D, R: N, S: D, T: D, V: D, W: D, Y: D,

[switch to compact view]
Comments [show]
Publications
[hide] Ozvegy C, Varadi A, Sarkadi B
Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
J Biol Chem. 2002 Dec 13;277(50):47980-90. Epub 2002 Oct 8., 2002-12-13 [PMID:12374800] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Doyle LA, Ross DD
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 2003 Oct 20;22(47):7340-58., 2003-10-20 [PMID:14576842] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD
Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.
Mol Pharmacol. 2003 Dec;64(6):1452-62., [PMID:14645676] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Mizuarai S, Aozasa N, Kotani H
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
Int J Cancer. 2004 Mar 20;109(2):238-46., 2004-03-20 [PMID:14750175] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Ozvegy-Laczka C, Varady G, Koblos G, Ujhelly O, Cervenak J, Schuetz JD, Sorrentino BP, Koomen GJ, Varadi A, Nemet K, Sarkadi B
Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.
J Biol Chem. 2005 Feb 11;280(6):4219-27. Epub 2004 Nov 22., 2005-02-11 [PMID:15557326] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Ozvegy-Laczka C, Koblos G, Sarkadi B, Varadi A
Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
Biochim Biophys Acta. 2005 Feb 1;1668(1):53-63., 2005-02-01 [PMID:15670731] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, Szabo K, Homolya L, Varadi A, Buday L, Keri G, Nemet K, Sarkadi B
Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
Cancer Res. 2005 Mar 1;65(5):1770-7., 2005-03-01 [PMID:15753373] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Henriksen U, Gether U, Litman T
Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
J Cell Sci. 2005 Apr 1;118(Pt 7):1417-26. Epub 2005 Mar 15., 2005-04-01 [PMID:15769853] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE
Single nucleotide polymorphisms modify the transporter activity of ABCG2.
Cancer Chemother Pharmacol. 2005 Aug;56(2):161-72. Epub 2005 Apr 19., [PMID:15838659] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Bhatia A, Schafer HJ, Hrycyna CA
Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers.
Biochemistry. 2005 Aug 16;44(32):10893-904., 2005-08-16 [PMID:16086592] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Henriksen U, Fog JU, Litman T, Gether U
Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.
J Biol Chem. 2005 Nov 4;280(44):36926-34. Epub 2005 Aug 17., 2005-11-04 [PMID:16107343] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Krishnamurthy P, Schuetz JD
Role of ABCG2/BCRP in biology and medicine.
Annu Rev Pharmacol Toxicol. 2006;46:381-410., [PMID:16402910] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Polgar O, Ozvegy-Laczka C, Robey RW, Morisaki K, Okada M, Tamaki A, Koblos G, Elkind NB, Ward Y, Dean M, Sarkadi B, Bates SE
Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization.
Biochemistry. 2006 Apr 25;45(16):5251-60., 2006-04-25 [PMID:16618113] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Sarkadi B, Homolya L, Szakacs G, Varadi A
Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.
Physiol Rev. 2006 Oct;86(4):1179-236., [PMID:17015488] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Li YF, Polgar O, Okada M, Esser L, Bates SE, Xia D
Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study.
J Mol Graph Model. 2007 Mar;25(6):837-51. Epub 2006 Aug 30., [PMID:17027309] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Assaraf YG
The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Drug Resist Updat. 2006 Aug-Oct;9(4-5):227-46. Epub 2006 Nov 7., [PMID:17092765] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Xu J, Peng H, Zhang JT
Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.
Curr Med Chem. 2007;14(6):689-701., [PMID:17346156] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Glavinas H, Kis E, Pal A, Kovacs R, Jani M, Vagi E, Molnar E, Bansaghi S, Kele Z, Janaky T, Bathori G, von Richter O, Koomen GJ, Krajcsi P
ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions.
Drug Metab Dispos. 2007 Sep;35(9):1533-42. Epub 2007 May 30., [PMID:17537873] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Wu CP, Shukla S, Calcagno AM, Hall MD, Gottesman MM, Ambudkar SV
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3287-96., [PMID:18089722] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Orban TI, Seres L, Ozvegy-Laczka C, Elkind NB, Sarkadi B, Homolya L
Combined localization and real-time functional studies using a GFP-tagged ABCG2 multidrug transporter.
Biochem Biophys Res Commun. 2008 Mar 14;367(3):667-73. Epub 2008 Jan 7., 2008-03-14 [PMID:18182157] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Hazai E, Bikadi Z
Homology modeling of breast cancer resistance protein (ABCG2).
J Struct Biol. 2008 Apr;162(1):63-74. Epub 2007 Dec 15., [PMID:18249138] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Polgar O, Robey RW, Bates SE
ABCG2: structure, function and role in drug response.
Expert Opin Drug Metab Toxicol. 2008 Jan;4(1):1-15., [PMID:18370855] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhellyi O, Nemet K, Heredi-Szabo K, Krajcsi P
Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance.
Ann Rheum Dis. 2009 Jul;68(7):1201-7. Epub 2008 Apr 8., [PMID:18397960] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Hegedus C, Szakacs G, Homolya L, Orban TI, Telbisz A, Jani M, Sarkadi B
Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays.
Adv Drug Deliv Rev. 2009 Jan 31;61(1):47-56. Epub 2008 Dec 24., 2009-01-31 [PMID:19135105] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Polgar O, Ediriwickrema LS, Robey RW, Sharma A, Hegde RS, Li Y, Xia D, Ward Y, Dean M, Ozvegy-Laczka C, Sarkadi B, Bates SE
Arginine 383 is a crucial residue in ABCG2 biogenesis.
Biochim Biophys Acta. 2009 Jul;1788(7):1434-43. Epub 2009 May 3., [PMID:19406100] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Hou YX, Li CZ, Palaniyandi K, Magtibay PM, Homolya L, Sarkadi B, Chang XB
Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport.
Biochemistry. 2009 Sep 29;48(38):9122-31., 2009-09-29 [PMID:19691360] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Pozza A, Perez-Victoria JM, Di Pietro A
Insect cell versus bacterial overexpressed membrane proteins: an example, the human ABCG2 transporter.
Methods Mol Biol. 2010;654:47-75., [PMID:20665261] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Su Y, Sinko PJ
Drug delivery across the blood-brain barrier: why is it difficult? how to measure and improve it?
Expert Opin Drug Deliv. 2006 May;3(3):419-35., [PMID:16640501] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Cserepes J, Szentpetery Z, Seres L, Ozvegy-Laczka C, Langmann T, Schmitz G, Glavinas H, Klein I, Homolya L, Varadi A, Sarkadi B, Elkind NB
Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization.
Biochem Biophys Res Commun. 2004 Jul 30;320(3):860-7., [PMID:15240127] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Gauthier C, Ozvegy-Laczka C, Szakacs G, Sarkadi B, Di Pietro A
ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.
Front Pharmacol. 2013 Nov 7;4:138. doi: 10.3389/fphar.2013.00138. eCollection 2013., [PMID:24312054] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Telbisz A, Hegedus C, Varadi A, Sarkadi B, Ozvegy-Laczka C
Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites.
Drug Metab Dispos. 2014 Apr;42(4):575-85. doi: 10.1124/dmd.113.055731. Epub 2014 Jan 2., [PMID:24384916] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Szafraniec MJ, Szczygiel M, Urbanska K, Fiedor L
Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
Drug Metab Rev. 2014 Nov;46(4):459-74. doi: 10.3109/03602532.2014.942037. Epub 2014 Jul 18., [PMID:25036722] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Krzyzanowski D, Bartosz G, Grzelak A
Collateral sensitivity: ABCG2-overexpressing cells are more vulnerable to oxidative stress.
Free Radic Biol Med. 2014 Nov;76:47-52. doi: 10.1016/j.freeradbiomed.2014.07.020. Epub 2014 Jul 23., [PMID:25064323] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Gal Z, Hegedus C, Szakacs G, Varadi A, Sarkadi B, Ozvegy-Laczka C
Mutations of the central tyrosines of putative cholesterol recognition amino acid consensus (CRAC) sequences modify folding, activity, and sterol-sensing of the human ABCG2 multidrug transporter.
Biochim Biophys Acta. 2015 Feb;1848(2):477-87. doi: 10.1016/j.bbamem.2014.11.006. Epub 2014 Nov 14., [PMID:25445676] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]